S100A8 and juvenile idiopathic arthritis: However, the combination of lower CRP and lower S100A8/9 or S100A12 levels increased the likelihood of high-level improvement (JIA-ACR100) 3 months after abatacept initiation; this combined assessment may have the potential to better predict disease-specific improvements in JIA.